Merck's Keytruda Combination Wins Expanded FDA Approval for Muscle Invasive Bladder Cancer

MT Newswires Live07-10 23:49

Merck's (MRK) pembrolizumab, alone or with berahyaluronidase alfa-pmph, each in combination with enfortumab vedotin-ejfv, won US Food and Drug Administration approval on Friday as neoadjuvant treatment before surgery followed by adjuvant treatment after cystectomy for adults with muscle-invasive bladder cancer.

The approval expands the regimen's previously authorized use from patients who were ineligible for cisplatin to all patients with muscle-invasive bladder cancer who are candidates for cystectomy.

The approval was based on a late-stage trial showing statistically significant improvements in event-free survival and overall survival compared with neoadjuvant gemcitabine and cisplatin, the FDA said.

Price: 124.05, Change: -1.02, Percent Change: -0.82

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment